Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer
Abstract
Endocrine resistance remains a major clinical challenge in estrogen receptor (ER)–positive breast cancer. Despite the encouraging results from clinical trials for the drugs targeting known survival signaling, relapse is still inevitable. There is an unmet need to discover new drug targets in the unknown escape pathways. Here, we report Nemo-like kinase (NLK) as a new actionable kinase target that endows previously uncharacterized survival signaling in endocrine-resistant breast cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 04, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-2961
Entities
People
- Chia-chia Liu
- Jamunarani Veeraraghavan
- Jin-ah Kim
- Lanfang Qin
- Ling Lin
- Martin J. Shea
- Matthew J Ellis
- Rachel Schiff
- Sang Hyeon Lee
- Shunqiang Li
- Suet Kee Loo
- Susan Hilsenbeck
- Tamika Mitchell
- Xian Wang
- Xiao-song Wang
- Xixi Cao
- Yiheng Hu
- Ying Tan
Organizations
- Baylor College of Medicine
- Cancer Prevention and Research Institute of Texas
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- National Institutes of Health
- Stand Up to Cancer
- Susan G. Komen for the Cure
- The Breast Cancer Research Foundation
- University of Pittsburgh
- Washington University in St. Louis